225240-71-1

Basic information

• Product Name: Ethyl 4-Methylpiperidine-4-carboxylate Hydrochloride
• Synonyms: Ethyl 4-Methylpiperidine-4-carboxylate Hydrochloride;Ethyl 4-methylpiperidine-4-carboxylate HCl
• CAS NO: 225240-71-1
• Molecular Formula: C₉H₁₇NO₂*ClH
• Molecular Weight: 207.7
• Mol File: 225240-71-1.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 259.9 °C at 760 mmHg
• Flash Point: 111 °C
• Appearance: /
• Vapor Pressure: 0.00991mmHg at 25°C
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: Ethyl 4-Methylpiperidine-4-carboxylate Hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: Ethyl 4-Methylpiperidine-4-carboxylate Hydrochloride(225240-71-1)
• EPA Substance Registry System: Ethyl 4-Methylpiperidine-4-carboxylate Hydrochloride(225240-71-1)

Safety Data

• Hazardous Substances Data: 225240-71-1(Hazardous Substances Data)

Usage

Uses

Ethyl 4-methylpiperidine-4-carboxylate, HCl

InChI:InChI=1/C9H17NO2.ClH/c1-3-12-8(11)9(2)4-6-10-7-5-9;/h10H,3-7H2,1-2H3;1H

Upstream product

• 142851-03-4 1-tert-butyl 4-ethyl piperidine-1,4-dicarboxylate 
• 189442-87-3 ethyl tert-butyl 4-methylpiperidine-1,4-dicarboxylate 

Downstream Products

• 1372544-52-9 1-{5-[7-Cyclohexyl-2-(3-ethyl-ureido)-benzothiazol-5-yl]-pyrimidin-2-yl}-4-methyl-piperidine-4-carboxylic acid 
• 1372548-42-9 ethyl 1-[5-[7-cyclohexyl-2-(ethylcarbamoylamino)-1,3-benzothiazol-5-yl]pyrimidin-2-yl]-4-methyl-piperidine-4-carboxylate 

Relevant articles and documents

FUSED TRICYCLIC BENZIMIDAZOLES DERIVATIVES AS MODULATORS OF TNF ACTIVITY

A series of tricyclic benzimidazole derivatives, in particular dihydro-1H- imidazo [1,2-a]benzimidazo le, dihydro-1H-pyrrolo [1,2-a]benzimidazo le, dihydro-1H- pyrazino[1,2-a]benzimidazole, dihydro-1H-[1,4]oxazino[4,3-a]benzimidazole and dihydrothiazolo[3,4-a]benzimidazolem, and analogues thereof, being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.

FUSED TRICYCLIC IMIDAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY

A series of substituted fused tricyclic imidazole derivatives, in particular dihydro- 1H-pyrano[4',3':4,5]imidazo[1,2-a]pyridine, 1,2,3,4-tetrahydroimidazo[1,2-a:5,4- c']dipyridine, dihydro-1H-pyrano[3',4':4,5]imidazo[1,2-a]pyridine and tetrahydro-6H- cyc

Design, synthesis and biological evaluation of α-substituted isonipecotic acid benzothiazole analogues as potent bacterial type II topoisomerase inhibitors

The discovery and optimisation of a new class of benzothiazole small molecules that inhibit bacterial DNA gyrase and topoisomerase IV are described. Antibacterial properties have been demonstrated by activity against DNA gyrase ATPase and potent activity against Staphylococcus aureus, Enterococcus faecalis, Streptococcus pyogenes and Haemophilus influenzae. Further refinements to the scaffold designed to enhance drug-likeness included analogues bearing an α-substituent to the carboxylic acid group, resulting in excellent solubility and favourable pharmacokinetic properties.